DaShenLin Pharmaceutical Group Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Guoqiang Ke

Chief executive officer

CN¥2.1m

Total compensation

CEO salary percentage	n/a
CEO tenure	5.2yrs
CEO ownership	0.02%
Management average tenure	no data
Board average tenure	no data

Recent management updates

Recent updates

CEO

Guoqiang Ke (41 yo)

5.2yrs

Tenure

CN¥2,140,500

Compensation

Mr. Guoqiang Ke is General Manager of DaShenLin Pharmaceutical Group Co., Ltd. from February 28, 2019. He was Deputy General Manager of DaShenLin Pharmaceutical Group Co., Ltd.from January 16, 2017 to Feb...

DaShenLin Pharmaceutical Group Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.43 in 1Q 2023)

DaShenLin Pharmaceutical Group Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

DaShenLin Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.28 in 2Q 2022)

DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: EPS: CN¥1.09 (vs CN¥0.83 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.32 in 2Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥1.00 (vs CN¥1.35 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.35 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.39 (vs CN¥0.41 in 2Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥1.12 in FY 2019)

New 90-day low: CN¥75.58

New 90-day high: CN¥105

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: CN¥76.99

New 90-day low: CN¥78.69

New 90-day high: CN¥99.20

Third quarter earnings released

DaShenLin Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day high: CN¥92.06

First half earnings released

New 90-day high - CN¥83.20

DaShenLin Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Compensation